Eikon Therapeutics, Inc.
About Eikon Therapeutics, Inc.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$83.0M
- Total assets
- $850.8M
- Market cap
- $485.1M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $485.1M
- Shares outstanding
- 54.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $83.0M.
- Trading 45% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Eikon Therapeutics, Inc..
Write a review
News about Eikon Therapeutics, Inc.
News & sentiment via Polygon.io
